BioArctic Secures Priority Review for Leqembi
In an exciting development for Alzheimer's treatment, BioArctic AB's (publ) partner announced that the Biologics License Application (BLA) for Leqembi (lecanemab), utilizing a subcutaneous autoinjector, has been granted Priority Review by Chinese authorities. This designation is significant as it refers to the approval process by the National Medical Products Administration (NMPA) in China.
Streamlining Treatment Options
The subcutaneous formulation, which was accepted for review earlier, represents an important milestone in making treatment accessible for patients with early Alzheimer's disease. If approved, patients may use this 500 mg dose at home instead of undergoing intravenous treatment in a hospital, thus simplifying the treatment process and enhancing comfort for patients and their care partners.
Importance of Priority Review
The Priority Review program aims to expedite the development of medicines with substantial clinical merit in China. Through this program, the NMPA will significantly shorten the assessment period for new treatments, allowing innovations like Leqembi to reach patients more swiftly.
The Need for Innovative Treatments
Currently, there are about 17 million individuals in China experiencing Mild Cognitive Impairment (MCI) or mild dementia resulting from Alzheimer's, and this number is projected to continue escalating. This indicates an increasing necessity for effective treatments that can significantly improve the lives of patients while reducing the strain on healthcare systems.
Leqembi's Market Presence
Leqembi was launched in June 2024 and is now available for use in the private market. Its inclusion in the recent "Commercial Insurance Innovative Drug List" reflects the commitment of the Chinese government to advance innovative therapeutic options and improve access to such treatments. As a result, insurance products covering Leqembi are expected to become available, further facilitating patient access to this vital treatment.
Research and Development Collaboration
Leqembi's creation stems from a collaboration between BioArctic and Eisai, with the antibody originally developed by BioArctic based on groundbreaking research into Alzheimer’s disease. Eisai oversees clinical development and commercialization efforts for Leqembi globally, while BioArctic retains rights for commercial activities in the Nordic region, gearing up for joint efforts there.
Global Reach of Leqembi
This groundbreaking treatment boasts approval in 53 countries and is under review in multiple regions, indicative of its worldwide potential. In the United States, Leqembi Iqlik™ is already authorized for subcutaneous dosing, presenting a convenient option for ongoing treatment.
Ongoing Clinical Trials
The clinical landscape continues to evolve, with ongoing studies, including Phase 3 trials for individuals with early Alzheimer’s showing promise. These initiatives, supported by robust partnerships among leading organizations, could transform how Alzheimer's disease is approached and treated globally.
Collaboration: BioArctic and Eisai
A long-standing collaboration between BioArctic and Eisai has focused on the development of innovative treatments for Alzheimer’s disease over the past years. Their strategic partnership has paved the way for the advancement of lecanemab, establishing a foundation for future endeavors in combating this challenging disease.
About BioArctic AB
BioArctic AB (publ) is a Swedish biopharma firm specializing in research-based innovations aimed at addressing neurodegenerative conditions. The company is at the forefront of developing Leqembi® (lecanemab), a breakthrough treatment that has illustrated an ability to slow the progression of Alzheimer’s disease. Besides Leqembi, BioArctic’s pipeline includes several other therapies targeting various neurological disorders.
Frequently Asked Questions
What is the significance of the Priority Review for Leqembi?
The Priority Review designation allows for expedited assessment of Leqembi, potentially speeding up its availability to patients in China.
How does the subcutaneous formulation benefit patients?
This formulation allows for easier administration at home, increasing convenience and comfort compared to intravenous treatments.
What is the current availability of Leqembi?
Leqembi was launched in China in 2024 and has recently been included in a commercial insurance drug list to enhance patient access.
What collaboration exists between BioArctic and Eisai?
BioArctic collaborates with Eisai in research and commercialization efforts, capitalizing on each company's strengths in drug development.
What other projects is BioArctic involved in?
In addition to Leqembi, BioArctic is exploring treatments for conditions like Parkinson's disease and ALS.
